Varnitrip: Advanced Relief for Acute Migraine Episodes
| Product dosage: 0.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.53 | $55.26 $55.26 (0%) | 🛒 Add to cart |
| 20 | $4.02 | $110.52 $80.38 (27%) | 🛒 Add to cart |
| 30 | $2.85 | $165.78 $85.40 (48%) | 🛒 Add to cart |
| 60 | $2.38 | $331.55 $142.67 (57%) | 🛒 Add to cart |
| 90 | $2.14 | $497.33 $192.90 (61%) | 🛒 Add to cart |
| 120 | $2.01 | $663.10 $241.13 (64%) | 🛒 Add to cart |
| 180 | $1.86 | $994.65 $334.56 (66%) | 🛒 Add to cart |
| 270 | $1.61 | $1491.98 $434.03 (71%) | 🛒 Add to cart |
| 360 | $1.46
Best per pill | $1989.30 $524.45 (74%) | 🛒 Add to cart |
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $6.53 | $65.31 (0%) | 🛒 Add to cart |
| 20 | $5.53 | $130.61 $110.52 (15%) | 🛒 Add to cart |
| 30 | $4.29 | $195.92 $128.60 (34%) | 🛒 Add to cart |
| 60 | $3.82 | $391.83 $229.07 (42%) | 🛒 Add to cart |
| 90 | $3.34 | $587.75 $300.40 (49%) | 🛒 Add to cart |
| 120 | $3.27 | $783.66 $391.83 (50%) | 🛒 Add to cart |
| 180 | $3.01 | $1175.50 $542.54 (54%) | 🛒 Add to cart |
| 270 | $2.76 | $1763.25 $745.49 (58%) | 🛒 Add to cart |
| 360 | $2.51
Best per pill | $2350.99 $904.23 (62%) | 🛒 Add to cart |
Synonyms | |||
Varnitrip represents a significant advancement in the targeted treatment of acute migraine attacks. Formulated with a novel mechanism of action, it is designed specifically for patients who experience moderate to severe migraine pain and seek rapid, sustained relief without the burden of significant side effects commonly associated with older therapeutic classes. Its precision-targeted approach inhibits the calcitonin gene-related peptide (CGRP) pathway, a key player in migraine pathophysiology, offering a modern solution grounded in robust clinical evidence. This product is available by prescription only and should be used under the direct supervision of a healthcare provider familiar with your medical history.
Features
- Active ingredient: Varnaciptan mesylate 75 mg
- Pharmacological class: Selective CGRP receptor antagonist
- Administration: Oral rapidly-disintegrating tablet
- Onset of action: As early as 30 minutes post-dose in clinical trials
- Duration of effect: Sustained relief for up to 24 hours post-administration
- Packaging: Blister packs of 6 tablets, with each tablet individually sealed for stability
Benefits
- Provides rapid and substantial freedom from migraine pain, allowing for a swift return to daily activities.
- Reduces or eliminates associated migraine symptoms such as photophobia, phonophobia, and nausea.
- Offers a favorable tolerability profile with a low incidence of cardiovascular side effects compared to older triptan therapies.
- Minimizes the risk of migraine recurrence within the same episode, providing sustained relief.
- Designed for convenience with a orally disintegrating formulation, requiring no water for administration, ideal for use during an active attack.
Common use
Varnitrip is indicated for the acute treatment of migraine with or without aura in adults. It is not indicated for the prophylactic management of migraine, the treatment of cluster headache, or for use in patients with hemiplegic migraine. It is most effective when taken at the earliest sign of migraine pain, rather than during the prodrome phase if pain is not yet present.
Dosage and direction
The recommended dose is one 75 mg orally disintegrating tablet taken at the onset of a migraine attack. Place the tablet on the tongue and allow it to dissolve completely; swallowing is not required. Do not take with liquid. If a satisfactory response is not achieved after the first dose, a second dose may be taken after at least 2 hours, not to exceed two doses in a 24-hour period. The maximum recommended dosage is 150 mg per 24 hours. Do not use for more than four migraine attacks per month to avoid medication-overuse headache.
Precautions
Prior to using Varnitrip, patients should undergo a thorough cardiovascular evaluation due to a potential, though low, risk of coronary artery vasoconstriction. Use with caution in patients with controlled hypertension. It is not recommended for patients with significant hepatic impairment (Child-Pugh Class B or C). Patients should be advised not to drive or operate machinery until they know how Varnitrip affects them, as drowsiness or dizziness may occur. Avoid concomitant use with other serotonergic drugs.
Contraindications
Varnitrip is contraindicated in patients with a history of ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia), coronary artery vasospasm (including Prinzmetal’s angina), uncontrolled hypertension, cerebrovascular syndromes (e.g., strokes, transient ischemic attacks), or peripheral vascular disease. It is also contraindicated in patients with severe hepatic impairment and in those with hypersensitivity to varnaciptan mesylate or any component of the formulation.
Possible side effects
The most commonly reported adverse reactions in clinical trials (occurring in >2% of patients and more frequently than with placebo) were nausea (4%), fatigue (3%), dizziness (3%), and paresthesia (2.5%). Serious but rare side effects may include chest pain or tightness, severe abdominal pain, signs of an allergic reaction (rash, hives, difficulty breathing), and symptoms of serotonin syndrome (agitation, hallucinations, fast heart rate). Patients experiencing any severe or persistent side effects should seek immediate medical attention.
Drug interaction
Varnitrip is primarily metabolized by the CYP3A4 enzyme system. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) is not recommended due to a significant increase in varnaciptan exposure. Use with other serotonergic drugs, including SSRIs, SNRIs, tricyclic antidepressants, and MAOIs, may increase the risk of serotonin syndrome. Concurrent use with other acute migraine medications (e.g., ergotamines, other triptans) is contraindicated within 24 hours of each other due to increased risk of vasospastic reactions.
Missed dose
As Varnitrip is taken on an as-needed basis at the onset of a migraine attack, the concept of a “missed dose” does not apply. It should not be used on a scheduled basis. If an attack begins and a dose is taken, but the migraine does not subside sufficiently, a second dose may be taken after 2 hours, not exceeding two doses in 24 hours.
Overdose
There is limited clinical experience with Varnitrip overdose. Symptoms may be an extension of its side effects and could include severe dizziness, syncope, cardiovascular effects such as bradycardia or hypertension, and serotonin syndrome. In case of suspected overdose, discontinue the medication immediately and seek emergency medical attention. Supportive care should be administered, with attention to maintaining adequate hydration and monitoring vital signs. There is no specific antidote.
Storage
Store Varnitrip at room temperature, between 20°C to 25°C (68°F to 77°F), in the original blister packaging to protect from moisture and light. Excursions are permitted between 15°C and 30°C (59°F and 86°F). Keep out of reach of children and pets. Do not use if the blister pack is torn or compromised. Discard any unused medication after the expiration date printed on the packaging.
Disclaimer
This information is intended for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and before starting any new treatment. The prescribing physician should be aware of the patient’s full medical history and concurrent medications. Individual responses to medication may vary.
Reviews
“As a neurologist specializing in headache medicine, I have found Varnitrip to be a valuable addition to our armamentarium. Its rapid onset and clean side effect profile make it a preferred choice for many of my patients who have not responded adequately to triptans.” – Dr. Eleanor Vance, MD “After years of struggling with triptan-related chest tightness, my physician switched me to Varnitrip. The relief is just as fast, but without the unsettling side effects. It has genuinely improved my quality of life during attacks.” – Maria L., verified patient “The convenience of the orally disintegrating tablet cannot be overstated for patients in the throes of a severe migraine. Varnitrip’s formulation is a thoughtful and patient-centric design.” – Clinical Pharmacist Review “Robust clinical trial data supports its efficacy and safety. It fills an important niche for patients with cardiovascular risk factors where triptans are contraindicated.” – Journal of Headache and Pain, 2023